Aprinoia Therapeutics (Aprinoia Therapeutics) Net-Net Working Capital : $-3.19 (As of Jun. 2023)

View and export this data going back to 2050. Start your Free Trial

What is Aprinoia Therapeutics Net-Net Working Capital?

In calculating the Net-Net Working Capital (NNWC), Benjamin Graham assumed that a company's accounts receivable is only worth 75% its value, its inventory is only worth 50% of its value, but its liabilities have to be paid in full. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. This is a conservative way of estimating the company's value.

Aprinoia Therapeutics's Net-Net Working Capital for the quarter that ended in Jun. 2023 was $-3.19.

The industry rank for Aprinoia Therapeutics's Net-Net Working Capital or its related term are showing as below:

APRI's Price-to-Net-Net-Working-Capital is not ranked ^*
in the Biotechnology industry.
Industry Median: 4
* Ranked among companies with meaningful Price-to-Net-Net-Working-Capital only.

Aprinoia Therapeutics Net-Net Working Capital Historical Data

The historical data trend for Aprinoia Therapeutics's Net-Net Working Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aprinoia Therapeutics Net-Net Working Capital Chart

Aprinoia Therapeutics Annual Data

Trend

Dec21

Dec22

Net-Net Working Capital

-1.86

-2.87

Aprinoia Therapeutics Semi-Annual Data
	Dec21	Jun22	Dec22	Jun23
Net-Net Working Capital	-1.86	-	-2.87	-3.19

Competitive Comparison of Aprinoia Therapeutics's Net-Net Working Capital

For the Biotechnology subindustry, Aprinoia Therapeutics's Price-to-Net-Net-Working-Capital, along with its competitors' market caps and Price-to-Net-Net-Working-Capital data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Aprinoia Therapeutics's Price-to-Net-Net-Working-Capital Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Aprinoia Therapeutics's Price-to-Net-Net-Working-Capital distribution charts can be found below:

* The bar in red indicates where Aprinoia Therapeutics's Price-to-Net-Net-Working-Capital falls into.

Aprinoia Therapeutics Net-Net Working Capital Calculation

Aprinoia Therapeutics's Net-Net Working Capital (NNWC) per share for the fiscal year that ended in Dec. 2022 is calculated as

	Net-Net Working Capital		(A: Dec. 2022 )
=	(Cash, Cash Equivalents, Marketable Securities	+	0.75 * Accounts Receivable	+	0.5 * Total Inventories	-	Total Liabilities
-	Preferred Stock	-	Minority Interest)	/	Shares Outstanding (EOP)
=	(1.221	+	0.75 * 0	+	0.5 * 0	-	81.093
-	0	-	0)	/	27.829
=	-2.87

Aprinoia Therapeutics's Net-Net Working Capital (NNWC) per share for the quarter that ended in Jun. 2023 is calculated as

	Net-Net Working Capital		(Q: Jun. 2023 )
=	(Cash, Cash Equivalents, Marketable Securities	+	0.75 * Accounts Receivable	+	0.5 * Total Inventories	-	Total Liabilities
-	Preferred Stock	-	Minority Interest)	/	Shares Outstanding (EOP)
=	(7.731	+	0.75 * 0	+	0.5 * 0	-	96.408
-	0	-	0)	/	27.829
=	-3.19

In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.

This is a conservative way of estimating the company's value.

Aprinoia Therapeutics (NAS:APRI) Net-Net Working Capital Explanation

One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.

Benjamin Graham looked for companies whose market values were less than two-thirds of their net-net value. They are collected under our Net-Net screener.

Aprinoia Therapeutics Net-Net Working Capital Related Terms

Thank you for viewing the detailed overview of Aprinoia Therapeutics's Net-Net Working Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Aprinoia Therapeutics (Aprinoia Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aprinoia Therapeutics Inc (NAS:APRI) » Definitions » Net-Net Working Capital

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

Aprinoia Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in protecting patients' brain health and changing clinical outcomes for a broad range of neurodegenerative diseases by developing novel, highly sensitive and selective diagnostic tools and novel therapeutics. Neurodegenerative diseases are relentless and largely fatal, resulting from progressive loss of nerve cells in the brain and, depending on the specific disorders, can affect a broad range of cognitive, behavioral, and motor functions, such as memory, thinking, speaking, walking, and breathing. It is developing several different diagnostic and therapeutic platforms such as abnormal protein aggregates of tau and alpha synuclein ("?-Syn") that are toxic to brain cells.

Aprinoia Therapeutics (Aprinoia Therapeutics) Headlines

No Headlines